您的位置: 首页 > 2018年5月 第49卷 第3期 > 文字全文
2023年7月 第38卷 第7期11
目录

2011—2016年铜绿假单胞菌耐药性变迁分析

The changes of drug resistance of Pseudomonas aeruginosa from 2011 to 2016

来源期刊: 广州医药 | 55-58 发布时间:2021-12-01 收稿时间:2025/11/13 17:22:10 阅读量:15
作者:
关键词:
铜绿假单胞菌抗菌药物耐药性
Pseudomonas aeruginosaAntibioticsDrug resistance
DOI:
10.3969/j.issn.1000-8535.2018.03.015
收稿时间:
2017-12-18 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 分析2011—2016年间铜绿假单胞菌分离株的耐药性及变迁情况, 为临床合理用药提供科学依据。方法 对2011年1月—2016年12月广州市第一人民院患者各类标本中分离到的铜绿假单胞菌2 257株进行细菌鉴定及药敏试验,并对耐药性变迁进行统计分析。结果 铜绿假单胞菌在痰液标本中的检出率最高为56.9%;6年铜绿假单胞菌平均耐药率以妥布霉素最低,为9.9%,对哌拉西林/他唑巴坦、头孢吡肟、头孢他啶、左氧氟沙星、环丙沙星、亚胺培南、庆大霉素等药物的耐药率均<20%,在2013年耐药率最低,此后三年逐年上升。结论 铜绿假单胞菌对广州市第一人民院常用抗生素的耐药率在近3年呈逐年上升趋势, 临床医师应根据药敏结果合理选择抗菌药物, 以提高疗效和减缓耐药菌的产生。
Objective To analyze the changes of drug resistance of Pseudomonas aeruginosa (Pae) and to provide basis for the use of antibiotics in clinic. Methods 2 257 strains of Pae were cultured and isolated in the First People Hospitalof Guangzhou from 2011 to 2016, API bacterial identification system was applied to carry out bacterial identification and K-B method was used for drug sensitivity analysis. Results Most of the Pae (56.9%) were detected from the sputum specimen. It showed the highest sensitivity to tobramycin. The drug resistance of Pae to piperacillin/tazobactam, cefepime, ceftazidime, levofloxacin, ciprofloxacin, imipenem and gentamicin in 2013 was the lowest and has been increasing year by year. Conclusion Pseudomonas aeruginosa isolated in our hospital showed a rising trend of clinical drug resistance in the past three years. It was of the top priority for clinicians to use antibiotics rationally to retard the production of drug resistant strains.
1、 ALOUSH V, NAVON N-VENEZEZIAS, SEIGMAN-IGRA Y, et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact [J]. Antimicrob Agents Chemother, 2006, 50(1): 43-48. ALOUSH V, NAVON N-VENEZEZIAS, SEIGMAN-IGRA Y, et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact [J]. Antimicrob Agents Chemother, 2006, 50(1): 43-48.
2、 TOLKER-NIELSEN T. Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities[J]. APMIS Suppl, 2014, 122(138):1-51. TOLKER-NIELSEN T. Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities[J]. APMIS Suppl, 2014, 122(138):1-51.
3、 GISKE C G, BUAR L, SUNDSFJORD A, et al. Alterations of porin, pumps, and penicillin-binding proteins in carbapenem resistant clinical isolates of Pseudomonas aeruginosa[J]. Microb Drug Resist, 2008, 14(1):23-30. GISKE C G, BUAR L, SUNDSFJORD A, et al. Alterations of porin, pumps, and penicillin-binding proteins in carbapenem resistant clinical isolates of Pseudomonas aeruginosa[J]. Microb Drug Resist, 2008, 14(1):23-30.
4、 SYED A, SIKANDAR S, TARRUNUM S, et al. Drug resistance profile and biofilm forming potential of Pseudomonas aeruginosa isolated from contact lenses in Karachi-Pakistan[J]. BMC Ophthalmol, 2013(13): 57. SYED A, SIKANDAR S, TARRUNUM S, et al. Drug resistance profile and biofilm forming potential of Pseudomonas aeruginosa isolated from contact lenses in Karachi-Pakistan[J]. BMC Ophthalmol, 2013(13): 57.
5、 许时菲.铜绿假单胞菌耐药机制的研究进展[J]. 内蒙中医药,2014,33(4): 119-120. 许时菲.铜绿假单胞菌耐药机制的研究进展[J]. 内蒙中医药,2014,33(4): 119-120.
6、 陈璐,查筑红,冷应蓉,等.铜绿假单胞菌的耐药性及耐药基因研究[J]. 中华医院感染学杂志,2014(8):1837-1839. 陈璐,查筑红,冷应蓉,等.铜绿假单胞菌的耐药性及耐药基因研究[J]. 中华医院感染学杂志,2014(8):1837-1839.
7、 周燕飞,庞艳,王斌.铜绿假单胞菌感染临床分布及耐药性分析[J]. 中华医院感染学杂志,2014,24(17): 4177-4178. 周燕飞,庞艳,王斌.铜绿假单胞菌感染临床分布及耐药性分析[J]. 中华医院感染学杂志,2014,24(17): 4177-4178.
8、 张祎博,孙景勇,倪语星,等.2004—2014年中国CHINET铜绿假单胞菌耐药性监测[J]. 中国感染与化疗杂志,2016,16(2):141-145. 张祎博,孙景勇,倪语星,等.2004—2014年中国CHINET铜绿假单胞菌耐药性监测[J]. 中国感染与化疗杂志,2016,16(2):141-145.
9、 袁慧峰,张琳,赵红星,等.重症监护病房铜绿假单胞菌感染的危险因素和耐药性分析[J]. 临床肺科杂志,2012,17(3):437-438. 袁慧峰,张琳,赵红星,等.重症监护病房铜绿假单胞菌感染的危险因素和耐药性分析[J]. 临床肺科杂志,2012,17(3):437-438.
10、 Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Twenty fourth informational supplement, 2014:M100-S24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Twenty fourth informational supplement, 2014:M100-S24.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录